Tramadol News and Research

RSS
Labopharm, Paladin Labs expand commercial relationship

Labopharm, Paladin Labs expand commercial relationship

Labopharm announces European approval of twice-daily tramadol-acetaminophen

Labopharm announces European approval of twice-daily tramadol-acetaminophen

USPTO issues Patent Notice of Allowance for CIP-TRAMADOL ER drug

USPTO issues Patent Notice of Allowance for CIP-TRAMADOL ER drug

Labopharm second-quarter total revenue increases to $6.8 million

Labopharm second-quarter total revenue increases to $6.8 million

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Labopharm launches antidepressant OLEPTRO for major depressive disorder in U.S.

Biovail second-quarter total revenues increase 23% to $238.8 million

Biovail second-quarter total revenues increase 23% to $238.8 million

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Etoricoxib better than opioid drug tramadol for postoperative pain: Study

Etoricoxib better than opioid drug tramadol for postoperative pain: Study

Cipher Pharmaceuticals second-quarter net revenues increase to $2.2 million

Cipher Pharmaceuticals second-quarter net revenues increase to $2.2 million

Expert to speak on challenges, issues in development, implementation of REMS

Expert to speak on challenges, issues in development, implementation of REMS

Labopharm amends debt facility agreement with Hercules Technology Growth Capital

Labopharm amends debt facility agreement with Hercules Technology Growth Capital

Cipher Pharmaceuticals reaches cumulative sales milestone for Lipofen

Cipher Pharmaceuticals reaches cumulative sales milestone for Lipofen

TheraQuest launches new analgesic product pipeline

TheraQuest launches new analgesic product pipeline

Labopharm comments on the outcome of patent-infringement litigation related to Ultram ER

Labopharm comments on the outcome of patent-infringement litigation related to Ultram ER

Study confirms Azilect as a selective MAO-B inhibitor

Study confirms Azilect as a selective MAO-B inhibitor

Labopharm completes joint venture with Gruppo Angelini

Labopharm completes joint venture with Gruppo Angelini

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

FDA approves Cipher's CIP-TRAMADOL ER for chronic pain

Biovail reports 27% increase in first-quarter 2010 total revenues

Biovail reports 27% increase in first-quarter 2010 total revenues

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Labopharm's first-quarter fiscal 2010 revenues from product sales decrease $0.4M to $3.2M

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010